Ioanna A. Kyprianou

Ioanna A. Kyprianou

Auto-generated profile, based on publicly available information

Ioanna A. Kyprianou

School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
PDF file
KKKonstantinos G Kyriakoulis
Konstantinos G Kyriakoulis
Anastasios KolliasAnastasios Kollias
Anastasios Kollias
IKIOANNIS KYRIAKOULIS
IOANNIS KYRIAKOULIS
IKIoanna A. Kyprianou
Ioanna A. Kyprianou
CPChrysso Papachrysostomou
Chrysso Papachrysostomou
DMDimitri P. Mikhailidis
Dimitri P. Mikhailidis
Background: Venous thromboembolism (VTE) is common among patients with severe coronavirus disease 2019 (COVID-19). Anticoagulation in hospitalized COVID-19 patients has been associated with survival benefit; however, the optimal thromboprophylaxis strategy has not yet been defined. Objective: To identify published guidance reports by national and international societies regarding thromboprophylaxis strategies in COVID-19 patients in different settings (outpatients, hospitalized, post-discharge). Methods: A systematic review of the literature (Pubmed/EMBASE) was conducted independently by two investigators. Results: Among 1942 initially identified articles, 33 guidance documents were included: 20 published by national and 13 by international societies. These documents provide recommendations mainly for hospitalized (97% of reports) and post-discharge (75%) COVID-19 patients, and less so for outpatients (34%). Thrombotic and bleeding risk stratification prior to any treatment decision is the cornerstone of all suggested thromboprophylaxis strategies; 81% of the documents recommend thromboprophylaxis for all hospitalized patients with a prophylactic dosage of low molecular weight heparin irrespective of VTE risk. Intermediate or therapeutic dose intensity is recommended in high VTE risk patients by 56% and 28% of documents, respectively. Mechanical thromboprophylaxis is suggested in case of high bleeding risk or contraindication to pharmacological thromboprophylaxis (59% of documents). Extended pharmacological thromboprophylaxis is recommended for patients with high VTE risk after hospital discharge (63% of documents). For non-hospitalized outpatients, 28% of documents recommend pharmacological thromboprophylaxis for high VTE risk. Conclusion: The current guidance identifies thromboprophylaxis in COVID-19 patients, especially during hospitalization, as of major importance for the prevention of VTE. Recommendations are derived from limited evidence from observational studies.

10 September 2020 in Phlebology: The Journal of Venous Disease
Verified
Journal Article
Closed access
PDF file
KKKonstantinos G Kyriakoulis
Konstantinos G Kyriakoulis
DKDamianos G. Kokkinidis
Damianos G. Kokkinidis
IKIoanna A Kyprianou
Ioanna A Kyprianou
CPChristos A Papanastasiou
Christos A Papanastasiou
PAParaschos Archontakis-Barakakis
Paraschos Archontakis-Barakakis
LPLeonidas Palaiodimos
Leonidas Palaiodimos
Coronavirus disease 2019 (COVID-19) does not only affect the respiratory system but appears to be a systemic disease. Venous thromboembolism is a common manifestation in hospitalized patients with COVID-19 with a reported incidence that is significantly higher compared to other acute viral infections. The pathophysiology mechanisms have not been fully explored and autopsy studies might enhance our understanding on this topic. Microthrombi formation occurs mainly in the pulmonary vasculature but can also occur in other organs. The high inflammatory burden related to COVID-19 seems to be associated with the coexisting coagulopathy. Concomitant manifestations of COVID-19, such as severe pneumonia, which has similar clinical presentation with pulmonary embolism (PE), and barriers related to strict isolation protocols are the two main reasons why PE diagnosis might be more challenging in patients with COVID-19. Medical societies have published guidance reports suggesting the administration of prophylactic anticoagulant therapy in hospitalized patients with COVID-19, but several questions regarding the optimal acute and long-term treatment of these patients remain unanswered.